The peroxisome proliferator-activated receptor-α (PPAR-α) agonist, AVE8134, attenuates the progression of heart failure and increases survival in rats

Acta Pharmacologica Sinica

Volumn 30, Issue 7, 2009, Pages 935-946

  Linz, Wolfgang ^a   Wohlfart, Paulus ^a   Baader, Manuel ^d   Breitschopf, Kristin ^a   Falk, Eugen ^b   Schäfer, Hans Ludwig ^b   Gerl, Martin ^c   Kramer, Werner ^b   Rütten, Hartmut ^a  

^a Therapeutic Department Cardiovascular Research   (Germany)

^b Therapeutic Department Metabolism   (Germany)

^c SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^d BioFocus DPI   (United Kingdom)

Author keywords

Fibrosis; Heart failure; Hypertrophy; Inflammation; Nitric oxide; Peroxisome proliferator activated receptor; Rat; Survival

Indexed keywords

2 METHYL 6 [3 (2 PHENYLOXAZOL 4 YLMETHOXY)PROPOXYMETHYL]BENZOIC ACID; ARGININE; AVE 8134; BRAIN NATRIURETIC PEPTIDE; CD36 ANTIGEN; CITRULLINE; CREATININE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; MACROPHAGE SCAVENGER RECEPTOR 1; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PRO BRAIN NATRIURETIC PEPTIDE; RAMIPRIL; ROSIGLITAZONE; SERINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBROSIS; HEART MUSCLE RELAXATION; HEART OUTPUT; HEART VENTRICLE HYPERTROPHY; HUMAN; HUMAN CELL; HYPERTENSION; LIFE EXPECTANCY; LOW DRUG DOSE; MALE; MONOCYTE; NONHUMAN; PROTEIN EXPRESSION; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; SURVIVAL RATE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BENZOIC ACIDS; BIOLOGICAL MARKERS; CARDIOTONIC AGENTS; CELL LINE; DISEASE PROGRESSION; HEART FAILURE; HEMODYNAMICS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MOLECULAR STRUCTURE; NITRIC OXIDE SYNTHASE TYPE III; OXAZOLES; PPAR ALPHA; RAMIPRIL; RATS; RATS, INBRED SHR; RATS, SPRAGUE-DAWLEY; SURVIVAL RATE; THIAZOLIDINEDIONES;

EID: 67651171418     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2009.58     Document Type: Article

References (50)

1. Staels B, Fruchart JC. Therapeutic roles of peroxisome proliferatoractivated receptor agonists. Diabetes 2005; 54: 2460-70.
2. Francis G, Fayard E, Picard F, Auwerx J. Nuclear Receptors and the control of metabolism. Ann Rev Physiol 2003; 65: 261-311.
3. Rangwala SM, Lazar MA. Peroxisome proliferator-activated receptor gamma in diabetes and metabolism. Trends Pharmacol Sci 2004; 25: 331-6.
4. Fruchart JC. Novel peroxisome proliferator activated receptor-alpha agonists. Am J Cardiol 2007; 100: n41-6.
5. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, et al. Activation of human aortic smooth muscle cells is inhibited by PPARα but not by PPAR? activators. Nature 1998; 393: 790-3.
6. Goya K, Sumitani S, Xu X, Kitamura T, Yamamoto H, Kurebayashi S, et al. Peroxisome proliferator-activated receptor α agonists increase nitric oxide synthase expression in vascular endothelial cells. Arterioscler Thromb Vasc Biol 2004; 24: 658-63.
7. Dragomir E, Tircol M, Manduteanu I, Voinea M, Simionescu M. Aspirin and PPAR-α activators inhibit monocytes chemoattractant protein-1 expression induced by high glucose concentration in human endothelial cells. Vasc Pharmacol 2006: 44: 440-9.
8. Finck BN. The PPAR regulatory system in cardiac physiology and disease. Cardiovasc Res 2007; 73: 269-77.
9. Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A, et al. The cardiac phenotype induced by PPARα overexpression mimics that caused by diabetes mellitus. J Clin Invest 2002; 109: 121-30.
10. Watanabe K, Fujii H, Takahashi T, Kodama M, Aizawa Y, Ohta Y, et al. Constitituve regulation of cardiac fatty acid metabolism through peroxisome proliferator-activated receptor alpha associated with agedependent cardiac toxicity. J Biol Chem 2000; 275: 22293-9.
11. Labinskyy V, Bellomo M, Chandler MP, Young ME, Lionetti V, Qanud K, et al. Chronic activation of PPARα with fenofibrate prevents alterations in cardiac metabolic phenotype without changing the onset of decompensation in pacing-induced heart failure. JPET 2007; 321: 165-71.
12. Brigadeau F, Gele P, Wibaux M, Marquie C, Martin-Nizard F, Tirpier G, et al. The PPARalpha activator fenofbrate slows down the progression of the left ventricular dysfunction in porcine tachycardia-induced cardiomyopathy. J Cardiovasc Pharmacol 2007; 49: 408-15.
13. Liang F, Wang F, Zhang S, Gardner DG. PPARα agonists inhibit hypertrophy of neonatal rat cardiac myocytes. Endocrinology 2003; 144: 4187-94.
14. Ogata T, Miyauchi T, Sakai S, Takanishi M, Irukayamy-Tomobe Y, Yamaguchi I. Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofbrate, partly by suppressing infammatory responses associated with the nuclear factor-kappa-B pathway. J Am Coll Cardiol 2004; 43: 1481-8.
15. Rose M, Balakumar P, Singh M. Ameliorative effect of combination of fenofbrate and rosiglitazone in pressure overload-induced cardiac hypertrophy in rats. Pharmacology 2007; 80: 177-84.
16. Schiffrin EL, Amiri F, Benkirane K, Iglarz M, Diep QN. Peroxisome proliferator-activated receptors. Vascular and cardiac effect in hypertension. Hypertension 2003; 42 (part 2): 664-8.
17. Shiomi T, Tsutsui H, Hayashidani S, Suematsu N, Ikeuchi M, Wen J, et al. Pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002; 106: 3126-32.
18. Itter G, Jung W, Juretschke P, Schölkens BA, Linz W. A model of chronic heart failure in spontaneously hypertensive rats (SHR). Laboratory Animals 2004; 38: 138-48.
19. Itter G, Jung W, Schölkens BA, Linz W. The isolated working heart model in infarcted rat hearts. Laboratory Animals 2005; 39: 178-93.
20. Linz W, Schäfer S, Afkham F, Gerl M, Schmidts HL, Rütten H. Vasopeptidase inhibition prevents target organ damage and improves survival in spontaneously hypertensive rats. JRAAS 2006; 7: 155-61.
21. Vishwanathan K, Tackett RL, Stewart T, Barlett MG. Determination of arginine and methylated arginines in human plasma by liquid chromatography- tandem mass spectroscopy. J Chromatogr 2000; 748: 157-66.
22. Lange M, Malyusz M. Improved determination of small amounts of free hydroyproline in biological fuids. Clin Chem 1994; 40: 1735-8.
23. Thum T, Borlak J. Reprogramming of gene expression in cultured cardiomyocytes and in explanted hearts by the myosin ATPase inhibitor butanedione monoxime. Transplantation 2001; 71: 543-52.
24. Schäfer M, Pönicke K, Heinroth-Hoffmann I, Brodde OE, Piper HM, Schlüter KD. Beta-adrenoceptor stimulation attenuates the hypertrophic effect of alpha-adrenoceptor stimulation in adult rat ventricular cardiomyocytes. J Am Coll Cardiol 2001; 37: 300-7.
25. Wohlfart P, Malinski T, Rütten H, Schindler U, Linz W, Schönafnger K, et al. Release of nitric oxide from endothelial cells stimulated by YC-1, an activator of soluble guanylyl cyclase. Br J Pharmacol 1999; 128: 1316-22.
26. Vasan RS. Biomarkers of cardiovascular disease - Molecular basis and practical considerations. Circulation 2006: 113; 2335-62.
27. Godfrey M, Majid DSA. Renal handling of circulating nitrates in anesthetized dogs. Am J Physiol Renal Physiol 1998; 275: F68-F73.
28. Pradham Ad. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327-34.
29. Danesh J. C-reactive protein and other circulating markers of infammation in the prediction of coronary heart disease. New Engl J Med 2004; 350: 1387-97.
30. Yin WH, Chen JW, Jen HL, Chiang MC, Huang WP, Feng AN, et al. Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure. Am Heart J 2004; 147: 931-8.
31. Frantz S, Hu K, Widder J, Bayer B, Witzel CC, Schmidt I, et al. Peroxisome proliferator activated-receptor agonism and left ventricular remodeling in mice with chronic myocardial infarction. Br J Pharmacol 2004; 141: 9-14.
32. Lygate CA, Hulbert K, Monfared M, Cole MA, Clarke K, Neubauer S. The PPARγ-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction. Cardiovasc Res 2003; 58: 632-7.
33. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 1-15.
34. Important revisions to the full prescribing information (labeling) highlighting increased risks of congestive heart failure associated with rosiglitazone. Available from: http://www.fda.gov/cder/drug/ InfoSheets/hCP/rosiglitazone200707hCP.htm
35. Pioglitazone may cause or exacerbate heart failure, particularly in certain patient populations. Available from: http://www.fda.gov/cder/ drug/InfoSheets/hCP/pioglitazonehCP.htm
36. Newaz M, Blanton A, Fedelis P, Oyekan A. NAD(P)H oxidase/nitric oxide interactions in peroxisome proliferator activated receptor (PPAR) α-mediated cardiovascular effects. Mut Res 2005; 579: 163-71.
37. Diep QN, Benkirane K, Amiri F, Cohn JS, Endemann D, Schiffrin EL. PPARα activator fenofibrate inhibits myocardial inflammation and fbrosis in angiotensin II-infused rats. J Mol Cell Cardiol 2004; 36: 295-304.
38. 2-terminal kinase pathway. Circulation 2004; 109: 904-10.
39. Duhaney TAS, Cui L, Rude MK, Lebrasseur NK, Ngoy S, De Silva DS, et al. Peroxisome proliferator-activated receptor α-independent actions of fenofibrate exacerbates left ventricular dilation and fibrosis in chronic pressure overload. Hypertension 2007; 49: 1084-94.
40. Yang Q, Nagano T, Shah Y, Cheung C, Ito S, Gonzalez FJ. The PPARα-humanized mouse: a model to investigate species differences in liver toxicity mediated by PPARα. Toxicol Sci 2008; 101: 132-9.
41. Campbell FM, Kozak R, Wagner A, Altarejos JY, Dyck RB, Belke DD, et al. A role for peroxisome proliferator-activated receptor α (PPAR α) in the control of cardiac malonyl-CoA levels. J Biol Chem 2002; 277: 4098-103.
42. McGarry JD, Leatherman GF, Foster DW J. Carnitine palmitoyltransferase I - the site of inhibition of hepatic fatty acid oxidation by malonyl CoA. J Biol Chem 1978; 253: 4128-36.
43. Ichihara S, Obata K, Yamada Y, Nagata K, Noda A, Ichihara G, et al. Attentuation of cardiac dysfunction by a PPARα agonist is associated with down-regulation of redox-regulated transcription factors. J Mol Cell Cardiol 2006; 41: 318-29.
44. Murakami H, Murakami R, Kambe F, Cao X, Takahashi R, Asai T, et al. Fenofbrate activates AMPK and increases eNOS phosphorylation in HUVEC. Biochem Biophys Res Commun 2006; 341: 973-8.
45. Ziegler-Heitbrock HW, Thiel E, Futterer A, Herzog V, Wirtz A, Riethmller G. Establishment of a human cell line (Mono Mac 6) with characteristics of mature monocytes. Int J Cancer 1988; 41: 456-61.
46. Cross AK, Richardson V, Ali SA, Palmer I, Taub DD, Rees RC. Migration responses of human monocytic cell lines to alpha- and beta-chemokine. Cytokine 1997; 9: 521-8.
47. Van Eck M, De Winther MP, Herijgers N, Havekes LM, Hofker MH, Groot Ph, et al. effect of human scavenger receptor class A overexpression in bone marrow-derived cells on cholesterol levels and atherosclerosis in ApoE-defcient mice. Arterioscler Thromb Vasc Biol 2000; 20: 2600-6.
48. Moore KJ, Kunjathoor VV, Koehn SL, Manning JJ, Tseng AA, Silver JM, et al. Loss of receptor-mediated lipid uptake via scavenger receptor A or CD36 pathways does not ameliorate atherosclerosis in hyperlipidemic mice. J Clin Invest 2005; 115: 2192-201.
49. Collot-Teixeira S, Martin J, McDermott-Roe C, Poston R, McGregor JL. CD36 and macrophages in atherosclerosis. Cardiovasc Res 2007; 75: 468-77.
50. Smeets PJH, Planavila A, van der Vusse GJ, van Bilsen M. Peroxisome proliferator-activated receptors and inflammation: take it to heart. Acta Physiol 2007; 191: 171-88.